RT Journal Article
SR Electronic
T1 Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 736
OP 740
DO 10.1136/hrt.2009.186189
VO 96
IS 10
A1 F Cuculi
A1 C C S Lim
A1 A P Banning
YR 2010
UL http://heart.bmj.com/content/96/10/736.abstract
AB Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.